VOLUNTARY ANNOUNCEMENT - THE FIRST PATIENT HAS BEEN DOSED IN A PHASE 1 CLINICAL STUDY OF HLX3901 INJECTION (DLL3xDLL3xCD3xCD28 TETRA-SPECIFIC ANTIBODY) FOR THE TREATMENT OF PATIENTS WITH ADVANCED SMALL CELL LUNG CANCER OR NEUROENDOCRINE CARCINOMA IN CHINESE MAINLAND